Researchers eye health benefit from AI
Monday, 14 June, 2021 - 11:45
Several exciting AI innovations are emerging from WA, and the world is watching.
John Konstantopoulos has over 20 years of commercial and technical experience, providing strategic advice to the electronics, healthcare and industrial sectors globally. He also has extensive experience in commercialisation, strategy development, product development, strategic marketing, and business development.
Mr Konstantopoulos has advised senior executives in some of the world's and Australia’s largest corporations on product commercialisation, development and digital transformation; and has driven growth in markets within Asia, US and Europe.
Mr Konstantopoulos is a co-founder and executive director of healthcare technology company Artrya, which develops artificial intelligence solutions for clinicians to accurately diagnose patients at risk of heart disease.
Rank | Company | # | |
---|---|---|---|
126th | Katana Capital | $3.71m | |
127th | Artrya | $3.69m | |
128th | icetana | $3.68m | |
129th | DigitalX | $3.59m |
Rank | Company | 1 Yr | 5 Yr |
---|---|---|---|
88th | Telix Pharmaceuticals">Telix Pharmaceuticals | 145.44% | 70.94% |
89th | Regis Healthcare">Regis Healthcare | 144.9% | 21.15% |
90th | Artrya">Artrya | 144.41% | 0% |
91st | Galicia Energy Corporation">Galicia Energy Corporation | 142.31% | -21.1% |
92nd | Universal Store Holdings">Universal Store Holdings | 141.06% | 0% |
NEWS: Tagged in FDA turns down Perth medtech | 17 Jun 2022 | |
NEWS: Tagged in Researchers eye health benefit from AI | 14 Jun 2021 | |
NEW ROLE: Co-Founder, Executive Product Director, Artrya | 17 Dec 2020 |
Several exciting AI innovations are emerging from WA, and the world is watching.
A local medtech focused on the early detection of heart disease has sought $40 million through an IPO, which will in part be used to fund the development and commercialisation of its software.
Local medtech Artrya has listed on the stock exchange, having earlier raised $40 million through an IPO to help commercialise its cardiac imaging software.
Artrya shares continued to drop this morning after the US Food and Drug Administration knocked back its AI-based coronary diagnostic product for commercial use.
A Perth-based artificial intelligence healthcare company has appointed a US health technology expert to its board.
Our board moves wrap includes Kate Hill, John Konstantopoulos, Jocelyn Bennett, Frank Knezovic, William Witham, Matthew Kay, Hayden Bartrop, Jessamyn Lyons, David Groombridge, Jacqueline Murray, Xavier Braud, Trevor Bradley.
Medical technology company Artrya Limited has appointed experienced executive Mathew Regan as the company’s new leader after its co-founder John Barrington resigned.
Position | Company | Year | Company's current rank |
---|---|---|---|
Co-Founder, Executive Product Director
|
2018 - 2023 | 127 |